Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajmg.a.37281 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Moss BRCA2 lacking the canonical DNA-binding domain promotes homologous recombination and binds to DNA.
Nucleic Acids Res
September 2025
Université Paris-Saclay, INRAE, AgroParisTech, Institut Jean-Pierre Bourgin for Plant Sciences (IJPB), 78000 Versailles, France.
BRCA2 is crucial for mediating homology-directed DNA repair (HDR) through its binding to single-stranded DNA (ssDNA) and the recombinases RAD51 and DMC1. Most BRCA2 orthologs have a canonical DNA-binding domain (DBD) with the exception of Drosophila melanogaster. It remains unclear whether such a noncanonical BRCA2 variant without DBD possesses a DNA-binding activity.
View Article and Find Full Text PDFRBM15 promotes COAD progression by regulating the m6A modification of TMC5.
Hereditas
August 2025
Department of Anesthesiology, Affiliated Hospital of Inner Mongolia Medical University, No.1 North Street, Huimin District, Hohhot, 010010, Inner Mongolia Autonomous Region, China.
Background: Colon adenocarcinoma (COAD) is a frequent digestive system malignancy with high mortality and poor prognosis. Transmembrane Channel-like 5 (TMC5) has been reported to play an oncological role in various cancers. However, the role and mechanism of TMC5 in COAD remain unclear.
View Article and Find Full Text PDFPharmacodynamic-Driven Sequence-Dependent Synergy Effects in Pemetrexed-Osimertinib Combination Against Non-Small Cell Lung Cancer (NSCLC): Optimizing Synergy Through Sequential Interval.
Pharmaceutics
August 2025
Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 211198, China.
Combining pemetrexed (PEM) with Osimertinib (OSI) improves outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), but optimal scheduling remains undefined. Sequential PEM → OSI strategies may outperform concurrent administration; however, the critical dosing interval determining synergy has not been explored. : PEM pharmacodynamics were divided into an OSI-antagonized early phase (S-phase arrest and DNA damage accumulation) and OSI-synergized late phase (DNA damage peak, apoptosis initiation, and feedback EGFR activation).
View Article and Find Full Text PDFLactylation-mediated miRNA regulation in cancer therapy resistance.
J Transl Med
August 2025
Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Therapeutic resistance in cancer is increasingly understood as a dynamic outcome of the interplay among tumour metabolism, epigenetic regulation, and immune modulation, rather than a consequence of genetic mutations alone. At this intersection, lactylation-a recently discovered lactate-derived post-translational modification (PTM)-acts as a molecular bridge linking metabolic rewiring to transcriptional and post-transcriptional control. Meanwhile, microRNAs (miRNAs) have emerged as essential regulators of metabolic adaptation and epigenetic plasticity.
View Article and Find Full Text PDFALKBH5-mediated mA demethylation modification of RAD51 inhibits osteogenic differentiation via promoting DNA damage in osteoporosis.
Mol Immunol
October 2025
Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Electronic address:
Osteoporosis (OP) is a metabolic disorder characterized by reduced bone mineral density and degeneration of bone tissue microarchitecture. Osteogenic differentiation plays a pivotal role in OP pathogenesis by facilitating new bone formation, preserving bone strength and density, and counteracting bone resorption. RNA epigenetic modifications have been increasingly implicated in multiple aspects of bone metabolism.
View Article and Find Full Text PDF